Novel therapies for alzheimer's disease: Potentially disease modifying drugs

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The two major neuropathologic hallmarks of Alzheimer's disease (AD) areextracellular Amyloid beta (AΒ ) plaques and intracellular neurofibrillary tangles (NFTs).Several additional pathogenic mechanisms likely play a role in the pathogenesis of thedisease, including inflammation, oxidative damage, ion disregulation and cholesterolmetabolism. A number of compounds have been developed, trying to interfere with theabove mentioned altered mechanisms. Conversely to symptomatic drugs available todate, these new compounds are supposed to modify pathological steps leading to AD,thus acting on the evolution of the disease. Some of them are under clinical testing,others are in preclinical phases of development. In this chapter, the main pathogenicsteps leading to neurodegeneration will be discussed, together with an update ofpotentially disease-modifying drugs under testing.

Original languageEnglish
Title of host publicationCognitive Impairment: Causes, Diagnosis and Treatments
PublisherNova Science Publishers, Inc.
Pages73-96
Number of pages24
ISBN (Print)9781608762057
Publication statusPublished - Apr 2009

Fingerprint

therapy
drugs
pathogenesis
damage
ions

ASJC Scopus subject areas

  • Physics and Astronomy(all)

Cite this

Galimberti, D., Fenoglio, C., & Scarpini, E. (2009). Novel therapies for alzheimer's disease: Potentially disease modifying drugs. In Cognitive Impairment: Causes, Diagnosis and Treatments (pp. 73-96). Nova Science Publishers, Inc..

Novel therapies for alzheimer's disease : Potentially disease modifying drugs. / Galimberti, Daniela; Fenoglio, Chiara; Scarpini, Elio.

Cognitive Impairment: Causes, Diagnosis and Treatments. Nova Science Publishers, Inc., 2009. p. 73-96.

Research output: Chapter in Book/Report/Conference proceedingChapter

Galimberti, D, Fenoglio, C & Scarpini, E 2009, Novel therapies for alzheimer's disease: Potentially disease modifying drugs. in Cognitive Impairment: Causes, Diagnosis and Treatments. Nova Science Publishers, Inc., pp. 73-96.
Galimberti D, Fenoglio C, Scarpini E. Novel therapies for alzheimer's disease: Potentially disease modifying drugs. In Cognitive Impairment: Causes, Diagnosis and Treatments. Nova Science Publishers, Inc. 2009. p. 73-96
Galimberti, Daniela ; Fenoglio, Chiara ; Scarpini, Elio. / Novel therapies for alzheimer's disease : Potentially disease modifying drugs. Cognitive Impairment: Causes, Diagnosis and Treatments. Nova Science Publishers, Inc., 2009. pp. 73-96
@inbook{ba0873efc0dd411a92f569148701aa36,
title = "Novel therapies for alzheimer's disease: Potentially disease modifying drugs",
abstract = "The two major neuropathologic hallmarks of Alzheimer's disease (AD) areextracellular Amyloid beta (AΒ ) plaques and intracellular neurofibrillary tangles (NFTs).Several additional pathogenic mechanisms likely play a role in the pathogenesis of thedisease, including inflammation, oxidative damage, ion disregulation and cholesterolmetabolism. A number of compounds have been developed, trying to interfere with theabove mentioned altered mechanisms. Conversely to symptomatic drugs available todate, these new compounds are supposed to modify pathological steps leading to AD,thus acting on the evolution of the disease. Some of them are under clinical testing,others are in preclinical phases of development. In this chapter, the main pathogenicsteps leading to neurodegeneration will be discussed, together with an update ofpotentially disease-modifying drugs under testing.",
author = "Daniela Galimberti and Chiara Fenoglio and Elio Scarpini",
year = "2009",
month = "4",
language = "English",
isbn = "9781608762057",
pages = "73--96",
booktitle = "Cognitive Impairment: Causes, Diagnosis and Treatments",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Novel therapies for alzheimer's disease

T2 - Potentially disease modifying drugs

AU - Galimberti, Daniela

AU - Fenoglio, Chiara

AU - Scarpini, Elio

PY - 2009/4

Y1 - 2009/4

N2 - The two major neuropathologic hallmarks of Alzheimer's disease (AD) areextracellular Amyloid beta (AΒ ) plaques and intracellular neurofibrillary tangles (NFTs).Several additional pathogenic mechanisms likely play a role in the pathogenesis of thedisease, including inflammation, oxidative damage, ion disregulation and cholesterolmetabolism. A number of compounds have been developed, trying to interfere with theabove mentioned altered mechanisms. Conversely to symptomatic drugs available todate, these new compounds are supposed to modify pathological steps leading to AD,thus acting on the evolution of the disease. Some of them are under clinical testing,others are in preclinical phases of development. In this chapter, the main pathogenicsteps leading to neurodegeneration will be discussed, together with an update ofpotentially disease-modifying drugs under testing.

AB - The two major neuropathologic hallmarks of Alzheimer's disease (AD) areextracellular Amyloid beta (AΒ ) plaques and intracellular neurofibrillary tangles (NFTs).Several additional pathogenic mechanisms likely play a role in the pathogenesis of thedisease, including inflammation, oxidative damage, ion disregulation and cholesterolmetabolism. A number of compounds have been developed, trying to interfere with theabove mentioned altered mechanisms. Conversely to symptomatic drugs available todate, these new compounds are supposed to modify pathological steps leading to AD,thus acting on the evolution of the disease. Some of them are under clinical testing,others are in preclinical phases of development. In this chapter, the main pathogenicsteps leading to neurodegeneration will be discussed, together with an update ofpotentially disease-modifying drugs under testing.

UR - http://www.scopus.com/inward/record.url?scp=84892126139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892126139&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892126139

SN - 9781608762057

SP - 73

EP - 96

BT - Cognitive Impairment: Causes, Diagnosis and Treatments

PB - Nova Science Publishers, Inc.

ER -